# US 2016/0256319 A1 · Intraocular shunt placement in the suprachoroidal space

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256319 A1
- Document ID: US20160256319A1
- Status: Published application
- Kind: A1
- Application number: 15/153,648
- Filed: 2016-05-12
- Published: 2016-09-08
- Earliest claimed: 2010-11-15
- Assignees: AqueSys, Inc.
- Applicants: AqueSys, Inc.
- Inventors: Christopher HORVATH; Ronald D. BACHE; Laszlo O. ROMODA; Guenther GRABNER; Herbert A. REITSAMER; John R. SAMPLES
- Web page: https://patentgrep.com/patent/US20160256319A1

## CPC

- A61F 9/00781: {Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment (drainage implants in general A61M27/002)}
- A61B 17/3415: {for introducing tubes or catheters, e.g. gastrostomy tubes, drain catheters (A61B17/3417 takes precedence; body piercing catheter guide needles A61M25/06)}
- A61B 17/3468: {for implanting or removing devices, e.g. prostheses, implants, seeds, wires (devices for implanting seeds A61M37/0069)}
- A61B 17/3417: {Details of tips or shafts, e.g. grooves, expandable, bendable; Multiple coaxial sliding cannulas, e.g. for dilating (syringe needles A61M5/32; dilators A61M29/00)}
- A61F 9/0008: {Introducing ophthalmic products into the ocular cavity or retaining products therein (putting in contact lenses A61F9/0061; introducing or retaining media in cavities of the body in general A61M31/00)}
- A61F 9/0017: {implantable in, or in contact with, the eye, e.g. ocular inserts}
- A61F 9/007: Methods or devices for eye surgery
- A61M 27/002: {Implant devices for drainage of body fluids from one part of the body to another (intraocular A61F9/00781; middle ear A61F11/202)}
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

Glaucoma can be treated by implanting an intraocular shunt into the eye. Such procedures can employ various deployment devices, shunts, and implantation techniques. A method for treating glaucoma can include positioning an intraocular shunt in eye tissue such that the shunt conducts fluid from the anterior chamber to the suprachoroidal space and delivers a pharmaceutical or biological agent to the eye.

## Claims

### Claim 1

A device for deploying an intraocular shunt, the device comprising:
a hollow sleeve;
a flexible hollow shaft in the sleeve, the shaft having a curved configuration while outside the sleeve and a less curved configuration, less curved than the curved configuration, while inside the sleeve; and
an intraocular shunt within the shaft, the shunt comprising a pharmaceutical or biological agent deliverable to an eye;
wherein the shaft, when in the curved configuration, is configured to guide the shunt along a scleral spur of the eye as the shunt is exposed from the shaft; and
wherein the shaft is configured to be withdrawn, in the less curved configuration, from the eye after the shunt is exposed from the shaft such that a distal portion of the shunt resides in a suprachoroidal space of the eye and a proximal portion of shunt resides in an anterior chamber of the eye.

### Claim 2 (depends on 1)

The device of claim 1, further comprising a housing, the housing comprising a proximal portion and a distal portion, the distal portion being movable within the proximal portion.

### Claim 3 (depends on 2)

The device of claim 2, wherein the distal portion of the housing comprises a stiff sleeve, the shaft being movably disposed within the sleeve.

### Claim 4 (depends on 2)

The device of claim 2, wherein the shaft comprises a curved portion, the curved portion being configured to match an angle of the sclera.

### Claim 5 (depends on 2)

The device of claim 2, wherein a distal end of the hollow shaft comprises a sharp tip.

### Claim 6 (depends on 1)

The device of claim 1, wherein a distal end of the sleeve comprises a protrusion to provide resistance against advancement of the device when the protrusion contacts an anatomical feature in the anterior chamber.

### Claim 7 (depends on 1)

The device of claim 1, wherein the pharmaceutical or biological agent comprises a coating on a surface of the shunt.

### Claim 8 (depends on 7)

The device of claim 7, wherein the pharmaceutical or biological agent comprises a coating on an exterior surface of the shunt.

### Claim 9 (depends on 7)

The device of claim 7, wherein the pharmaceutical or biological agent comprises a coating on an interior surface of the shunt.

### Claim 10 (depends on 1)

The device of claim 1, wherein a portion of the shunt is impregnated with the pharmaceutical or biological agent.

### Claim 11 (depends on 1)

The device of claim 1, wherein the pharmaceutical or biological agent comprises a time-release pharmaceutical or biological agent.

### Claim 12

A method for implanting a shunt in a suprachoroidal space of an eye, the method comprising:
providing a device comprising: a housing; a deployment mechanism at least partially disposed within the housing; and a flexible hollow shaft coupled to the deployment mechanism and disposed within the shaft in a less curved configuration, less curved than a curved configuration, wherein the shaft holds an intraocular shunt, the shunt comprising a pharmaceutical or biological agent deliverable to the eye, the shaft being configured to guide the shunt along a scleral spur of an eye as the shunt is exposed from the shaft;
inserting the device into the eye;
advancing the shaft out of the housing, whereby the shaft transitions from the less curved configuration to the curved configuration; and
exposing the shunt from the shaft along a curved pathway, defined by the shaft in the curved configuration, within the eye such that a proximal portion of the shunt resides in and receives fluid from an anterior chamber of an eye and a distal portion of the shunt resides in and directs the fluid to the suprachoroidal space.

### Claim 13 (depends on 12)

The method of claim 12, wherein the eye comprises a corneal limbus, and the inserting comprises inserting the shaft into the eye posterior to the corneal limbus.

### Claim 14 (depends on 12)

The method of claim 12, wherein prior to the exposing, the method further comprises injecting a drug into the suprachoroidal space.

### Claim 15 (depends on 14)

The method of claim 14, wherein the drug comprises a steroid or antifibrotic agent.

### Claim 16 (depends on 12)

The method of claim 12, wherein the device comprises a sleeve, the method further comprising withdrawing the shaft into the sleeve, whereby the shaft changes from the curved configuration to the less curved configuration.

### Claim 17 (depends on 12)

The method of claim 12, wherein the pharmaceutical or biological agent comprises a coating on a surface of the shunt.

### Claim 18 (depends on 17)

The method of claim 17, wherein the pharmaceutical or biological agent comprises a coating on an exterior surface of the shunt.

### Claim 19 (depends on 17)

The method of claim 17, wherein the pharmaceutical or biological agent comprises a coating on an interior surface of the shunt.

### Claim 20 (depends on 12)

The method of claim 12, wherein a portion of the shunt is impregnated with the pharmaceutical or biological agent.

### Claim 21 (depends on 12)

The method of claim 12, wherein the pharmaceutical or biological agent comprises a time-release pharmaceutical or biological agent.
